HomeNewsIndiaSII's COVID-19 vaccine Covovax now available for 12-17 age group at private centres

SII's COVID-19 vaccine Covovax now available for 12-17 age group at private centres

A dose of Covovax will cost Rs 900 plus GST at private vaccination centres, in addition to a hospital service charge of Rs 150.

May 02, 2022 / 21:24 IST
Representative image

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.

A dose of Covovax will cost Rs 900 plus GST, in addition to a hospital service charge of Rs 150, they told PTI.

The move followed the recommendation of the National Technical Advisory Group on Immunisation (NTAGI) that the COVID-19 jab can be administered in the age group of 12-17 years.

Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years. In his letter, Singh had stated that the Pune-based firm wanted to provide Covovax to private hospitals at a per-dose rate of Rs 900 plus Goods and Services Tax (GST).

"Those aged 12-17 age group can now opt for Covovax shot at private hospitals. The provision for the same has been made at the CoWIN portal on Monday evening," an official source told PTI. India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group, subject to certain conditions, on March 9.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Currently, children aged 12 to 14 years are vaccinated with Biological E's intramuscular vaccine Corbevax, while those in the 15-18 age group are being administered Bharat Biotech's Covaxin at government vaccination centres.

PTI
first published: May 2, 2022 09:24 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347